Cannabis Rescheduling 2026: Why the Real Trade Is a Rotation

Tilray (TLRY) is back in the green. Canopy Growth (CGC) has bounced. SNDL is moving on volume. Every cannabis headline in the last three weeks has been about the April 23 rescheduling order, and the names getting the most attention are, predictably, the ones that have always gotten the most attention. They are the ones listed on the Nasdaq.

That is exactly the problem. The most important cannabis trade of the next twelve months is not Tilray going up. It is the rotation between Tilray and the U.S. multistate operators that are not yet on a major exchange — and that rotation has not started.

What the April 23 Rescheduling Actually Did

On April 23, 2026, the Justice Department and DEA moved two narrow categories of marijuana from Schedule I to Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a state medical marijuana license. The order took effect April 28 on publication in the Federal Register. Section 280E no longer applies to state-licensed medical operations. A federal DEA registration pathway is now open to state medical licensees, with a June 22 filing deadline to preserve operating status during review. A broader administrative hearing on rescheduling all marijuana, including adult-use, runs June 29 through July 15.

Adult-use cannabis remains Schedule I. Hemp-derived THC is unaffected. The carve-out is medical only. That distinction is the entire point.

Why Trulieve, Green Thumb, and Curaleaf Should Carve Out Medical and Uplist

The three largest U.S. multistate operators — Trulieve (OTC: TCNNF), Green Thumb (OTC: GTBIF), and Curaleaf (OTC: CURLF) — now have a federally legal mechanism for the first time in modern history. State-licensed medical marijuana is a Schedule III substance. The exchanges have always pointed to Schedule I as the binding obstacle to listing plant-touching U.S. cannabis. That obstacle is gone for the medical side of the business.

The play is mechanical. Each operator separates its state-licensed medical operations into a standalone subsidiary, registers that subsidiary with the DEA under the expedited pathway, and uplists it to the NYSE or Nasdaq.

Trulieve is the easiest candidate. Florida is medical-only, which means most of TCNNF’s revenue already qualifies under the new federal definition. A carve-out is closer to a relabeling than a restructuring.

Green Thumb is the highest-quality balance sheet in the sector. GTI has been consistently profitable, has retained the majority of operating cash flow since 2019, and is the only major MSO widely cited as having paid its federal taxes on time. The carve-out work is operationally harder because medical and adult-use revenue are intermingled in its core markets — but a Green Thumb medical subsidiary would arrive at a listing committee with audited financials that already pass institutional scrutiny.

Curaleaf has the most complicated footprint and the most upside. A U.S.-listed medical subsidiary combined with Curaleaf’s existing European medical business would create a global medical cannabis platform no competitor could replicate quickly.

The standard objection — that a carve-out leaves the adult-use business orphaned in an OTC parent — misreads the optics. The adult-use business does not disappear. It keeps generating cash, and it carries embedded option value on the June 29 hearing. If the broader rescheduling passes, the adult-use entity gets recombined or listed separately. If it does not, the medical entity has already captured the institutional premium. The optionality runs in one direction.

The Capital Trapped in Tilray, Organigram, and SNDL

Here is the part of the trade no one is talking about.

Most generalist investors who want cannabis exposure today own Tilray (TLRY), Organigram (OGI), or SNDL. Not because these are the best operators in the space. Because they are listed on Nasdaq and the U.S. MSOs are not. That is the entire reason the money is parked there. It is a structural artifact of the exchange-listing problem, not a fundamental endorsement of the Canadian licensed-producer model.

The fundamental story in the Canadian LPs is, charitably, exhausted:

• Tilray is down roughly 96% over five years. Share count is up nearly 500% since the 2018 U.S. debut. Q2 fiscal 2026 revenue grew 3% year-over-year. Cash burn continues.

• Organigram trades near tangible book and depends on European expansion to generate any growth narrative.

• SNDL is increasingly a Canadian alcohol and convenience retailer that happens to have a cannabis segment.

The Canadian adult-use market is a textbook case of oversupply, price compression, and regulatory restriction. Seven years of full federal legalization in Canada has not produced a single profitable scaled operator.

The Rotation From Canadian LPs to U.S. MSOs Is One-Directional

Once a Trulieve, Green Thumb, or Curaleaf medical subsidiary lists on a major exchange, the institutional logic of holding the Canadian names collapses. A U.S.-listed medical MSO offers materially better unit economics, a real and growing end market, a now-favorable tax structure, and a domestic regulatory tailwind that the Canadian LPs cannot access.

The capital that has been trapped in TLRY, OGI, and SNDL because there was nowhere else to go inside an institutional mandate will not stay there once an alternative exists. It will rotate. The marginal dollar of new cannabis allocation will go to the newly listed U.S. operators, and a meaningful portion of the existing dollar will follow within two to four quarters.

This is the second leg of the bull case for the U.S. MSOs, and it is arguably the larger one. The 280E benefit is mechanical and finite. The capital rotation is structural, recurring, and only begins once the listings exist.

Why the Big Three Aren’t Acting Like Companies About to Uplist

None of the three are currently behaving like companies that expect to be on a major exchange in the next twelve months. Investor relations across Trulieve, Green Thumb, and Curaleaf has been almost entirely reactive for three years: quarterly releases, the obligatory conference attendance, the occasional Bloomberg hit when a policy headline moves the sector.

There is very little proactive retail outreach. Very little effort to educate the next generation of cannabis investors who were not active in the 2018 or 2021 cycles. Very little of the narrative-building that the rotation thesis actually depends on. Let’s call a spade a spade, their current IR departments are awful & just cash checks.

Multiple expansion will not come from the existing holder base. The existing base is exhausted, underwater, and tax-sensitive. It will come from new entrants — retail investors who have never owned cannabis, advisors who have been waiting for a listing to add a sleeve, family offices that have been waiting for 280E relief, and generalist funds that cannot own OTC paper. Reaching that audience is not passive. It requires sustained outreach across the channels where those investors actually consume information, and it requires that outreach to begin before the listing, not after.

What This Means for Cannabis Investors Right Now

The investors who buy on day one of an uplisting are the investors who already knew the story on day zero. If a company starts building its retail and advisor audience the morning of the press release, it captures only the passive ETF and index flows. If the work starts now — six to twelve months ahead — the company also captures the active demand that has been primed by months of narrative-building, plus the Canadian-LP rotation as it arrives.

The difference between those two outcomes is several multiple turns. On companies the size of Curaleaf or Trulieve, several multiple turns is a measurable share of the entire market capitalization. It is the difference between shareholders front-running multiple expansion and simply receiving it after the fact.

The catalyst is the exchange listing. The fuel is the capital trapped in Tilray, Organigram, and SNDL. The accelerant is the investor outreach. The right move for any MSO board is to authorize all three in the same quarter and to start telling the story now.

For investors, the asymmetry is on the U.S. operators ahead of the listings, not the Canadian LPs that have already had their headline pop.